Passage Bio will reduce its workforce by 75%. This follows tough feedback from the FDA regarding its lead gene therapy. The FDA did not support a single-arm trial for the PBFT02 candidate. Passage Bio has also launched a strategic review for the company. This review includes exploring options like a merger, sale, or partnership.
Philadelphia, Pennsylvania
https://www.fiercebiotech.com/biotech/passage-launches-strategic-review-and-75-layoffs-after-gene-therapy-path-blocked-fda